Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

Rudolf A. de Boer, Gilles De Keulenaer, Johann Bauersachs, Dirk Brutsaert, John G. Cleland, Javier Diez, Xiao Jun Du, Paul Ford, Frank R. Heinzel, Kenneth E. Lipson, Theresa McDonagh, Natalia Lopez-Andres, Ida G. Lunde, Alexander R. Lyon, Piero Pollesello, Sanjay K. Prasad, Carlo G. Tocchetti, Manuel Mayr, Joost P.G. Sluijter, Thomas Thum & 8 others Carsten Tschöpe, Faiez Zannad, Wolfram Hubertus Zimmermann, Frank Ruschitzka, Gerasimos Filippatos, Merry L Lindsey, Christoph Maack, Stephane Heymans

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction. and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.

Original languageEnglish (US)
Pages (from-to)272-285
Number of pages14
JournalEuropean Journal of Heart Failure
Volume21
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Translational Medical Research
Fibrosis
Heart Failure
Therapeutics
Myocarditis
Cicatrix
Heart Diseases
Biomarkers
Myocardial Infarction
Hypertension
Inflammation
Phenotype
Education

Keywords

  • Biomarkers
  • Fibroblast
  • Fibrosis
  • Heart failure
  • Imaging
  • Matrix
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. / de Boer, Rudolf A.; De Keulenaer, Gilles; Bauersachs, Johann; Brutsaert, Dirk; Cleland, John G.; Diez, Javier; Du, Xiao Jun; Ford, Paul; Heinzel, Frank R.; Lipson, Kenneth E.; McDonagh, Theresa; Lopez-Andres, Natalia; Lunde, Ida G.; Lyon, Alexander R.; Pollesello, Piero; Prasad, Sanjay K.; Tocchetti, Carlo G.; Mayr, Manuel; Sluijter, Joost P.G.; Thum, Thomas; Tschöpe, Carsten; Zannad, Faiez; Zimmermann, Wolfram Hubertus; Ruschitzka, Frank; Filippatos, Gerasimos; Lindsey, Merry L; Maack, Christoph; Heymans, Stephane.

In: European Journal of Heart Failure, Vol. 21, No. 3, 01.03.2019, p. 272-285.

Research output: Contribution to journalReview article

de Boer, RA, De Keulenaer, G, Bauersachs, J, Brutsaert, D, Cleland, JG, Diez, J, Du, XJ, Ford, P, Heinzel, FR, Lipson, KE, McDonagh, T, Lopez-Andres, N, Lunde, IG, Lyon, AR, Pollesello, P, Prasad, SK, Tocchetti, CG, Mayr, M, Sluijter, JPG, Thum, T, Tschöpe, C, Zannad, F, Zimmermann, WH, Ruschitzka, F, Filippatos, G, Lindsey, ML, Maack, C & Heymans, S 2019, 'Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology', European Journal of Heart Failure, vol. 21, no. 3, pp. 272-285. https://doi.org/10.1002/ejhf.1406
de Boer, Rudolf A. ; De Keulenaer, Gilles ; Bauersachs, Johann ; Brutsaert, Dirk ; Cleland, John G. ; Diez, Javier ; Du, Xiao Jun ; Ford, Paul ; Heinzel, Frank R. ; Lipson, Kenneth E. ; McDonagh, Theresa ; Lopez-Andres, Natalia ; Lunde, Ida G. ; Lyon, Alexander R. ; Pollesello, Piero ; Prasad, Sanjay K. ; Tocchetti, Carlo G. ; Mayr, Manuel ; Sluijter, Joost P.G. ; Thum, Thomas ; Tschöpe, Carsten ; Zannad, Faiez ; Zimmermann, Wolfram Hubertus ; Ruschitzka, Frank ; Filippatos, Gerasimos ; Lindsey, Merry L ; Maack, Christoph ; Heymans, Stephane. / Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. In: European Journal of Heart Failure. 2019 ; Vol. 21, No. 3. pp. 272-285.
@article{05dc6ae0e22e43d4afd3dc18b308d6ff,
title = "Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology",
abstract = "Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction. and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.",
keywords = "Biomarkers, Fibroblast, Fibrosis, Heart failure, Imaging, Matrix, Prognosis",
author = "{de Boer}, {Rudolf A.} and {De Keulenaer}, Gilles and Johann Bauersachs and Dirk Brutsaert and Cleland, {John G.} and Javier Diez and Du, {Xiao Jun} and Paul Ford and Heinzel, {Frank R.} and Lipson, {Kenneth E.} and Theresa McDonagh and Natalia Lopez-Andres and Lunde, {Ida G.} and Lyon, {Alexander R.} and Piero Pollesello and Prasad, {Sanjay K.} and Tocchetti, {Carlo G.} and Manuel Mayr and Sluijter, {Joost P.G.} and Thomas Thum and Carsten Tsch{\"o}pe and Faiez Zannad and Zimmermann, {Wolfram Hubertus} and Frank Ruschitzka and Gerasimos Filippatos and Lindsey, {Merry L} and Christoph Maack and Stephane Heymans",
year = "2019",
month = "3",
day = "1",
doi = "10.1002/ejhf.1406",
language = "English (US)",
volume = "21",
pages = "272--285",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

AU - de Boer, Rudolf A.

AU - De Keulenaer, Gilles

AU - Bauersachs, Johann

AU - Brutsaert, Dirk

AU - Cleland, John G.

AU - Diez, Javier

AU - Du, Xiao Jun

AU - Ford, Paul

AU - Heinzel, Frank R.

AU - Lipson, Kenneth E.

AU - McDonagh, Theresa

AU - Lopez-Andres, Natalia

AU - Lunde, Ida G.

AU - Lyon, Alexander R.

AU - Pollesello, Piero

AU - Prasad, Sanjay K.

AU - Tocchetti, Carlo G.

AU - Mayr, Manuel

AU - Sluijter, Joost P.G.

AU - Thum, Thomas

AU - Tschöpe, Carsten

AU - Zannad, Faiez

AU - Zimmermann, Wolfram Hubertus

AU - Ruschitzka, Frank

AU - Filippatos, Gerasimos

AU - Lindsey, Merry L

AU - Maack, Christoph

AU - Heymans, Stephane

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction. and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.

AB - Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction. and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.

KW - Biomarkers

KW - Fibroblast

KW - Fibrosis

KW - Heart failure

KW - Imaging

KW - Matrix

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85060971328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060971328&partnerID=8YFLogxK

U2 - 10.1002/ejhf.1406

DO - 10.1002/ejhf.1406

M3 - Review article

VL - 21

SP - 272

EP - 285

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 3

ER -